{"filings":[{"id":1027797,"accession_number":"0001193125-26-269493","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2026-06-12T20:19:09+00:00","items":["5.07"],"status":"ready","headline":"Whitehawk Therapeutics shareholders elect three Class III directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Behzad Aghazadeh, Richard Maroun, and Emma Reeve elected as Class III directors with 26.7M, 27.7M, and 27.7M votes for, respectively.","Advisory say-on-pay passed with 22.9M for, 6.0M against, 3.6M abstain.","Ratification of BDO USA as auditor for FY 2026 passed with 34.8M for, 1.1M against, 4.4M abstain.","Approximately 82% of voting power (40.4M shares) present, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584277,"accession_number":"0001193125-26-234890","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2026-05-21T21:16:19+00:00","items":["8.01","9.01"],"status":"ready","headline":"Whitehawk Therapeutics expands ADC pipeline with option for CPT113 in up to five new programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Option agreement with Hangzhou DAC provides access to CPT113 for up to five internally developed ADC programs, including dual-payload variations.","DXC006 data from Hangzhou DAC accepted for oral presentation at ASCO; J&J disclosed an ADC using CPT113 at AACR.","PTK7-directed HWK-007 completed first dose cohort at 2 mg/kg, enrolling second cohort at 4 mg/kg; MUC16-directed HWK-016 enrolling first cohort at 2.5 mg/kg.","Phase 1 dose-escalation data for HWK-007 and HWK-016 expected in first half of 2027; IND for HWK-206 anticipated mid-2026.","Whitehawk retains global rights and full program control for new ADCs; anticipates IND submissions for multiple programs over next 12-24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50443,"accession_number":"0001193125-26-220656","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2026-05-13T12:08:41+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sells 4.33M shares at $3.92/share and 17.99M pre-funded warrants at $3.9199/warrant.","PIPE includes existing investors Avoro Capital, QVT, Coastlands, KVP, ADAR1, Acuta, StemPoint, Invus, and executives.","Expected close May 14, 2026; net proceeds for working capital and ADC pipeline advancement.","Cash runway extended into second half of 2028.","Lock-up agreements for executives/directors: 60 days post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92765,"accession_number":"0001193125-26-210615","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Whitehawk Therapeutics Q1 net loss $22.2M; cash $123M funds into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.2M for Q1 2026 vs net income of $73.0M in Q1 2025, which included an $87.4M gain on sale of Aadi Subsidiary.","Cash, cash equivalents and short-term investments of $123.0M as of March 31, 2026, down from $145.7M at Dec 31, 2025; expected to fund operations into 2028.","R&D expenses of $17.2M, including $5.3M development milestone to WuXi Biologics, up from $8.8M in Q1 2025.","Phase 1 trials for HWK-007 and HWK-016 continue enrollment; IND for HWK-206 in small-cell lung cancer/neuroendocrine tumors on track for mid-2026.","Initial Phase 1 data for pipeline candidates expected in the first half of 2027."],"consensus_eps_estimate":-0.3641,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103870,"accession_number":"0001193125-26-103117","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.","Cash, equivalents and ST investments $145.7M at YE2025 (up from $47.2M); cash runway into 2028.","HWK-007 (PTK7) and HWK-016 (MUC16) ADCs both actively recruiting Phase 1 trials in lung, ovarian, endometrial cancers.","HWK-206 IND submission for small-cell lung cancer and neuroendocrine tumors planned mid-2026; Phase 1 start Q3 2026.","Margaret Dugan appointed CMO in December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120144,"accession_number":"0001193125-25-268134","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Whitehawk Therapeutics reports Q3 net loss of $17.7M, cash $162.6M, IND filings on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $17.7M vs $12.5M in Q3 2024; no revenue reported.","Cash, equivalents and short-term investments $162.6M as of Sept 30, 2025, up from $47.2M at Dec 31, 2024; runway into 2028.","IND submissions for HWK-007 and HWK-016 planned by year-end 2025; HWK-206 by mid-2026.","PTK7 confirmed as broadly expressed tumor target through analysis presented at AACR-NCI-EORTC.","Management expects initial clinical data readouts across portfolio from current cash position."],"consensus_eps_estimate":0.068,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":7145000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136715,"accession_number":"0000950170-25-104592","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.","Cash, equivalents & short-term investments $177.2M at June 30, 2025 (vs $47.2M Dec 31, 2024).","IND filings on track: HWK-007 and HWK-016 by year-end 2025; HWK-206 by mid-2026.","Cash anticipated to fund operations into 2028, enabling initial clinical data readouts."],"consensus_eps_estimate":0.5032,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":7145000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153936,"accession_number":"0001193125-25-140810","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Whitehawk Therapeutics shareholders elect three Class II directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class II directors elected: Anupam Dalal (18.5M for, 5.0M withheld), Mohammad Hirmand (19.4M for, 4.2M withheld), David Lennon (19.4M for, 4.2M withheld).","Board size decreased from 10 to 9 directorships upon opening of polls.","Advisory vote on executive compensation passed: 18.9M for, 4.7M against, 14k abstentions.","Ratification of BDO USA as auditor for FY2025 approved with 28.1M for, 524k against, 101k abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153935,"accession_number":"0001628280-25-023788","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.","Revenue $7.1M from FYARRO sales through March 25, 2025, date of divestiture to Kaken for $102.4M.","Cash and equivalents $231.1M at March 31, 2025 (vs $47.2M Dec 31, 2024) after closing $100M PIPE.","Expects cash of ~$185M after transaction payments, funding operations into 2028.","Oncology ADC pipeline: three assets targeting PTK7, MUC16, SEZ6; first IND on track for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":7145000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172588,"accession_number":"0001193125-25-068845","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K/A","filed_at":"2025-03-31T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Whitehawk closes sale of Aadi Subsidiary for $102.4M; pro forma cash $131M; FY2024 pro forma loss $25.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.","Pro forma balance sheet as of Dec 31, 2024 shows cash & equivalents of $131.1M.","Estimated gain on sale of $93.2M recorded; pro forma FY2024 net loss improves to $25.2M from historical $63.7M.","Aadi revenue ($26.0M) and operating expenses ($64.3M) removed from pro forma statement.","Stockholder approval obtained February 28, 2025; company retains no FYARRO program revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172589,"accession_number":"0001193125-25-063253","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Whitehawk completes sale of Aadi Subsidiary to Kaken for $102.4M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of 100% of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC. closed on March 25, 2025.","Cash purchase price of $102.4 million after adjustments paid by Purchaser.","Pro forma financial information to be filed by amendment within four business days.","Deal previously announced on December 19, 2024 under Stock Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172587,"accession_number":"0001193125-25-056708","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01","5.03"],"status":"ready","headline":"Aadi Bioscience relaunches as Whitehawk Therapeutics; reports FY2024 net loss $63.7M, $100M PIPE closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to Whitehawk Therapeutics; stock begins trading under 'WHWK' on Nasdaq effective March 19, 2025.","Closed $100M PIPE financing; pending divestiture of FYARRO business to Kaken Pharmaceuticals.","Cash position $47.2M at Dec 31, 2024; expected $170-180M after transactions, funding operations into 2028.","FY2024 total revenue $26.0M from FYARRO; net loss $63.7M vs $65.8M in 2023.","ADC portfolio: three assets targeting PTK7, MUC16, SEZ6; goal to bring all to IND within 15 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172586,"accession_number":"0001193125-25-045605","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","5.07","7.01","9.01"],"status":"ready","headline":"Aadi Bioscience closes $100M PIPE; stockholders approve divestiture of FYARRO business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $100M from PIPE led by Ally Bridge Group; 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.","Stockholders approved sale of FYARRO business to KAKEN INVESTMENTS INC. (16.6M for, 3.5M against).","Equity plan amended to increase shares from 2.0M to 8.3M; annual reserve increase to 5% of outstanding.","Proceeds from PIPE and FYARRO sale, plus existing cash, expected to fund operations into 2028.","PIPE use includes upfront payments to WuXi Biologics and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189577,"accession_number":"0001193125-24-282407","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.","Licenses three pre-clinical ADC programs (MUC16, PTK7, SEZ6) from WuXi Biologics; upfront $44M total.","Raises $100M via PIPE: 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.","Appoints Baiteng Zhao, Ph.D. (ex-ProfoundBio CEO) to Board; he committed $3M in PIPE.","Stockholder support agreements secured for ~36% of shares; termination fee $3.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189576,"accession_number":"0001628280-24-045465","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.","Net loss of $12.5M for Q3 2024 vs $16.3M for Q3 2023; operating expenses $20.6M incl $2.6M restructuring.","Cash, equivalents, and short-term investments $62.6M as of Sep 30, 2024; expected to fund ops into 2H 2026.","Completed wind-down of PRECISION1 trial; Phase 2 trials for EEC and NETs enrolled 24 and 12 patients.","Comprehensive strategic review ongoing to maximize shareholder value; no timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":18744000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206084,"accession_number":"0001193125-24-228322","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aadi Bioscience wins arbitration; panel finds no breach, no damages to EOC","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitration panel issued Final Award on Sept 26, 2024, in favor of Aadi Bioscience.","Panel concluded Aadi did not breach the December 2020 EOC License Agreement.","EOC Pharma sought monetary damages; none awarded.","Dispute began in June 2022, centered on alleged failure to provide manufacturing info.","Outcome removes a significant legal overhang for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206083,"accession_number":"0001193125-24-222116","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aadi Bioscience approves retention bonuses for CEO ($390K) and CFO ($220K) through Mar 2025 or change of control","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO David J. Lennon eligible for $390,000 retention bonus if employed through Mar 31, 2025 or Change of Control.","CFO Scott Giacobello eligible for $220,000 retention bonus under same conditions.","If terminated without cause or resign for good reason before retention date, severance payment equal to bonus (subject to release).","Retention bonus program approved by Compensation Committee on Sept 15, 2024; letters executed Sept 18, 2024.","No change in at-will employment status; bonus is not part of base compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206082,"accession_number":"0001193125-24-205370","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CMO Loretta Itri resigns; Executive Chairman Neil Desai steps down on Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Dr. Loretta Itri voluntarily resigns effective Oct 1, 2024; receives 12 months severance pay plus COBRA reimbursement.","Executive Chairman Neil Desai terminated effective Oct 1, 2024; receives severance per agreement; remains on board.","Dr. Itri enters consulting arrangement: 10 hrs/month, $8,000 monthly retainer, initial 3-month term.","Both executives continue vesting in equity awards during consulting/board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206081,"accession_number":"0001193125-24-203889","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Aadi halts PRECISION1 trial for TSC1/TSC2 cancers; cuts R&D staff 80%, extends cash runway into 2H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.","FYARRO Q2 2024 sales of $6.2M; company will focus on FYARRO commercial business for PEComa.","Workforce reductions: 22 employees (32% total) and 80% of R&D staff; non-recurring charges estimated $2.2-2.5M in Q3 2024.","Cash runway extended into at least 2H 2026; company hired advisory firm for comprehensive strategic review to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206080,"accession_number":"0001628280-24-035390","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.","Net loss of $14.6M vs. $18.0M in Q2 2023; cash and investments $78.6M as of June 30, 2024.","Two-thirds interim analysis of fully enrolled PRECISION1 trial expected in Q3 2024.","Enrollment ongoing in Phase 2 trials for endometrial cancer and neuroendocrine tumors.","Cash runway expected to fund operations into Q4 2025 based on current plans."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":11532000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223113,"accession_number":"0001628280-24-027826","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aadi Bioscience shareholders approve director elections, say-on-pay, and auditor ratification at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Caley Castelein (9.95M for, 1.91M withheld) and Neil Desai (8.17M for, 3.68M withheld) as Class I directors.","Advisory vote on executive compensation passed with 8.97M for, 2.60M against, 282K abstentions.","Ratified BDO USA as independent auditor for FY 2024: 13.46M for, 635K against, 1.00M abstentions.","Total shares represented 15.1M, ~62% of voting power, establishing a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223112,"accession_number":"0001628280-24-021381","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.","Net loss $18.3M vs $15.2M in Q1 2023; cash $88.3M expected to fund operations into Q4 2025.","PRECISION1 trial fully enrolled; two-thirds interim analysis expected Q3 2024, full data early 2025.","Terminated Mirati/BMS collaboration for adagrasib combo; prioritizing Phase 2 trials in EEC and NETs.","Management expects return to sales growth in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":5353000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223111,"accession_number":"0001628280-24-014876","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aadi Bioscience amends FYARRO supply agreement with Fresenius Kabi, extends term to July 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment effective March 31, 2024 extends supply agreement for FYARRO through July 31, 2024 (or later agreed date).","Revised pricing, forecasting, compliance terms, and minimum purchase obligations for FYARRO from Fresenius Kabi.","Contains other customary terms for biotech manufacturing; full amendment to be filed in subsequent periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242610,"accession_number":"0001628280-24-010791","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).","Net loss $65.8M for FY2023 vs $60.5M in 2022; cash $108.8M funding into Q4 2025.","PRECISION1 trial enrollment on track to complete by May 2024; two-thirds interim analysis expected Q3 2024.","Phase 2 trials in accelerated endometrial cancer (EEC) and neuroendocrine tumors (NETs) actively enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259994,"accession_number":"0001193125-23-295566","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.","TSC2 arm (n=18): 11% ORR (2 PRs, 1 confirmed), 28% clinical benefit rate, 50% had ≥5 prior lines.","No new safety signals; one grade 2 pneumonitis resolved; safety consistent with mTOR class.","80 patients now enrolled; two-thirds interim analysis expected 3Q 2024; trial completion by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259993,"accession_number":"0001628280-23-037568","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience reports Q3 2023 results; no financial details in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for Q3 2023 results issued on November 8, 2023.","No revenue, EPS, or other specific figures are included in this filing text.","Investors need to review the full press release for complete financial data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":18028000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259991,"accession_number":"0001628280-23-037882","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K/A","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience reports Q3 FYARRO sales $6M (+40% YoY); net loss $16.3M; PRECISION1 interim on track for Dec 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.","Cash, equivalents & investments $119.3M as of Sep 30, 2023, expected to fund operations into 2025.","PRECISION1 interim analysis on first third of patients (n=40) on track for mid-December 2023.","Dave Lennon appointed President and CEO in early October 2023.","Phase 2 trials initiated for endometrial cancer (nab-sirolimus + letrozole) and neuroendocrine tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":18028000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259992,"accession_number":"0001193125-23-248461","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.","Compensation: $640,000 base salary, up to 60% annual bonus, $240,000 sign-on (cash + RSUs), option for 490,000 shares.","Board increased from 8 to 9; Lennon appointed as Class II director. Company adopted 2023 Inducement Plan reserving 600,000 shares.","Press release highlights Lennon’s Novartis background and FYARRO pipeline expansion into endometrial, neuroendocrine cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277264,"accession_number":"0001628280-23-028411","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.","Net loss $18.0M for Q2 2023 (vs $18.3M prior year); cash $134.9M expected to fund into 2025.","PRECISION1 trial interim analysis on 40 patients with appropriate follow-up expected before end of 2023.","Phase 2 trials in endometrial cancer (nab-sirolimus + letrozole) and NETs to initiate in Q4 2023.","First patient dosed in Phase 1/2 KRAS G12C trial with adagrasib (Mirati collaboration)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":12069000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295157,"accession_number":"0001628280-23-022421","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aadi Bioscience annual meeting elects directors, says-on-pay passes, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class III directors: Aghazadeh (8.36M for), Maroun (9.87M), Reeve (9.87M).","Advisory say-on-pay approved: 9.74M for, 0.28M against, 17K abstentions.","Shareholders voted for annual say-on-pay frequency (9.83M for 1 year); next vote by 2029.","Ratified BDO USA as auditor for FY2023: 13.85M for, 73K against, 3K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295156,"accession_number":"0001628280-23-017031","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience reports Q1 2023 FYARRO sales of $5.9M, net loss $15.2M; PRECISION 1 interim analysis expected end 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.","Net loss $15.2M vs $13.9M in Q1 2022; cash $151.2M expected to fund operations into 2025.","PRECISION 1 trial enrolling evenly in TSC1/2 arms; >15 tumor types; interim efficacy analysis on 40 patients expected by year-end 2023.","Appointed Dr. Mohammad Hirmand to board; Phase 1/2 KRAS G12C combo trial with adagrasib expected to start dosing in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":5867000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315730,"accession_number":"0001628280-23-009345","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).","Net loss $60.5M for FY2022 vs $110.1M in FY2021 (prior year incl $74.2M impairment).","Cash $172.6M at Dec 31, 2022; cash runway into 2025 after $72.5M Q4 financing.","PRECISION-1 trial preliminary data on TSC1/TSC2 alterations expected Q2 2023.","Appointed Dr. Mohammad Hirmand to Board; collaboration with Mirati on adagrasib combo trial start Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315727,"accession_number":"0001193125-23-082149","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K/A","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aadi Bioscience discloses compensation for interim CEO Scott Giacobello: quarterly bonus, option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Giacobello appointed Interim CEO and President effective March 15, 2023; remains CFO.","Quarterly bonus of $43,000 (prorated) approved for interim role.","Eligible for annual cash bonus at 90% of base salary based on performance objectives.","Received stock option for 100,000 shares vesting over 4 years with standard schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315729,"accession_number":"0001193125-23-059077","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.","CFO Scott Giacobello appointed Interim CEO and President effective March 15, 2023, while retaining CFO role.","Founder Neil Desai, Ph.D., continues as Executive Chairman and will assist with leadership transition.","Board has initiated a search for a permanent CEO; Giacobello's interim role ends when successor is appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315728,"accession_number":"0001193125-23-012507","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment extends contract term to March 31, 2024 (or later date if agreed).","Pricing and minimum purchase quantity obligations for Fyarro were updated and revised.","Agreement covers clinical and commercial manufacturing of Fyarro (sirolimus albumin-bound).","Contains customary biotech manufacturing terms; full agreement to be filed later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334076,"accession_number":"0001193125-22-300219","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aadi Bioscience amends bylaws to revise director nomination procedures and conform to Delaware law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended and restated bylaws effective Dec 6, 2022, adding requirement for stockholders to deliver Rule 14a-19 compliance evidence 5 business days before meeting.","Revised procedures for stockholder director nominations and proposals to align with recent DGCL amendments.","Updated provisions regarding directors, Board committees, and officers; made ministerial and clarifications changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334075,"accession_number":"0001193125-22-292703","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"AADI Bioscience regains compliance with Nasdaq audit committee independence rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Non-compliance resulted from Dr. Karin Hehenberger not qualifying as independent per Nasdaq Listing Rule 5605(c)(2)(A).","Board removed Hehenberger from Audit Committee and appointed Caley Castelein, M.D., who meets independence requirements.","Audit Committee now consists of Emma Reeve (chair), Richard Maroun, and Caley Castelein; company believes compliance restored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334074,"accession_number":"0001193125-22-280757","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Net product sales of FYARRO $4.2M in Q3 2022, up 24% from Q2; net loss $14.5M (vs $87.1M in Q3 2021).","Cash $183M as of Sep 30, 2022; cash runway extended into 2025 after $72.5M PIPE financing.","Founder/CEO Neil Desai appointed Executive Chairman; COO Brendan Delaney succeeds as President & CEO effective Jan 1, 2023.","Delaney receives $624K base salary, 60% bonus target, option for 150K shares; Board expanded to 8.","PRECISION 1 trial on track for preliminary data H1 2023; Mirati collaboration on adagrasib/nab-sirolimus combo expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351489,"accession_number":"0001193125-22-249235","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Aadi Bioscience raises $72.5M in PIPE financing to extend cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE includes 3,373,526 shares at $12.50 and 2,426,493 pre-funded warrants at $12.4999 with $0.0001 exercise price.","Gross proceeds ~$72.5M; expected close Sept. 26, 2022, subject to customary conditions.","Management participated for ~$750,000; led by a life sciences fund with existing investors.","Proceeds to fund PRECISION 1 trial, FYARRO commercial efforts, and general working capital.","Cash runway expected into 2025; preliminary PRECISION 1 data anticipated in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351488,"accession_number":"0001193125-22-216844","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.","Net loss $18.3M (vs $1.5M in Q2 2021), includes $3.7M impairment charge.","Cash and equivalents $118.7M; expected to fund operations into 2024.","PRECISION 1 trial (TSC1/TSC2) enrollment ongoing; preliminary data expected 1H23.","Permanent J-code (J9331) for FYARRO effective July 1, 2022 from CMS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":5744000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368864,"accession_number":"0001193125-22-185324","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.","Aadi disputes EOC's allegations of material breach; believes termination is for convenience.","Aadi had received $14M upfront and $1M milestone; lost potential $257M in milestones and royalties.","No further payments from EOC expected; Aadi loses exclusive development/commercialization partner for China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368863,"accession_number":"0001193125-22-176646","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aadi Bioscience stockholders elect two directors, ratify BDO as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anupam Dalal elected with 11,291,829 votes for and 454,197 withheld; 3,353,501 broker non-votes.","Karin Hehenberger elected with 11,726,212 votes for and 19,814 withheld; 3,353,501 broker non-votes.","Ratification of BDO USA LLP as auditor for FY 2022 received 15,019,683 for, 66,252 against, 13,592 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368862,"accession_number":"0001193125-22-148067","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience Q1 2022: FYARRO sales $2.3M; net loss $13.9M; first patient dosed in PRECISION 1 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.","Net loss for Q1 2022 was $13.9M vs $5.5M in Q1 2021; operating expenses $16.1M vs $4.2M.","Cash and equivalents $129.8M as of Mar 31, 2022, expected to fund operations into 2024.","First patient dosed in PRECISION 1 Phase 2 tumor-agnostic trial for TSC1/TSC2 altered tumors; initial data expected H1 2023.","Permanent J-code (J9331) for FYARRO granted, effective Jul 1, 2022; partnerships with Foundation Medicine and Tempus for trial enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":2307000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388109,"accession_number":"0001193125-22-078484","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aadi Bioscience enters $75M ATM equity offering agreement with Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility allows Aadi to sell up to $75M in common stock at its discretion.","Cowen will receive 3.0% commission on gross proceeds from any shares sold.","Sales will be made on Nasdaq under existing shelf registration statement (S-3).","Aadi has no obligation to sell any shares; program effective March 17, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388108,"accession_number":"0001193125-22-077792","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.","Cash and equivalents $149M as of Dec 31, 2021, expected to fund operations into 2024.","Q4 2021 net loss $16M vs net income $7.8M in Q4 2020; full year net loss $110.7M.","Phase 2 PRECISION 1 trial (TSC1/TSC2 alterations) open; initial data expected H1 2023.","Operating expenses Q4 $16.9M, up from $5.7M; G&A increased due to commercial buildout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388107,"accession_number":"0001193125-22-012763","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.","Agreement effective through Dec 31, 2022; covers clinical and commercial supply for US and Canada.","Aadi has minimum purchase obligations; failure triggers additional payment to Fresenius Kabi.","Price fixed but subject to increase under specified circumstances; includes labeling/packaging services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406041,"accession_number":"0001193125-21-337294","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2021-11-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aadi Bioscience receives FDA approval for FYARRO in advanced malignant PEComa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved FYARRO (sirolimus protein-bound particles) for adult patients with advanced unresectable or metastatic malignant PEComa.","FYARRO is the first and only FDA-approved treatment for advanced malignant PEComa, an ultra-rare sarcoma.","In pivotal AMPECT trial, overall response rate was 39% (12/31); median duration of response not reached after median 36-month follow-up.","Launch planned for Q1 2022; investor conference call scheduled for today at 8:30 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406040,"accession_number":"0001193125-21-325243","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.","Ended Q3 with $161.4M cash; expected runway into 2024 post merger & $155M PIPE.","Net loss $87.2M for Q3, primarily from $74.2M non-cash impairment related to merger.","Appointed Brendan Delaney COO, Loretta Itri CMO (Q4), Scott Giacobello CFO (Nov 28).","Plan to initiate registrational trial in TSC1/TSC2 tumors by end 2021 or early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-19.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":120000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406039,"accession_number":"0001193125-21-315472","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.","Compensation: $450k base salary, bonus up to 45% of base, and option for 200k shares vesting over 4 years.","Giacobello was CFO of GW Pharma (acquired by Jazz for $7.2B); led EPIDIOLEX launch with $296M first-year sales.","Company faces PDUFA date Nov 26, 2021 for lead drug FYARRO in malignant PEComa.","Lance Thibault, interim CFO since July 2021, will leave the role on the effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425054,"accession_number":"0001193125-21-282412","cik":1422142,"company_name":"Whitehawk Therapeutics, Inc.","ticker":"WHWK","form_type":"8-K/A","filed_at":"2021-09-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Aadi Bioscience files historical audited financials of acquired private company showing $32.6M deficit","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Old Aadi reported net loss of $3.5M for 2020, revenue of $14.6M (primarily $14M license revenue).","Accumulated deficit of $32.6M as of Dec 31, 2020; cash and equivalents of $4.5M.","Auditor's report includes substantial doubt about going concern due to recurring losses and negative cash flows.","As of Dec 31, 2020, the company had $14.3M payable to related party Celgene and $9M convertible promissory notes.","Merger with Aadi Bioscience, Inc. closed Aug 26, 2021; these are the acquired entity's historical financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":218900000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-24T23:59:59+00:00|425054"}